A modified CtPif1 helicase and its application
By modifying CtPif1 helicase, its binding stability with polynucleotides is enhanced, and the problems of excessively fast movement of polynucleotides and low sequencing accuracy in nanopore sequencing are solved, and stable control under the action of electric fields is achieved and efficient identification.
Patent Information
- Application Number
- CN202310903123.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-21
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2043-07-21
AI Technical Summary
In nanopore sequencing technology, single-stranded polynucleotides pass through nanopores too fast, making it difficult to distinguish the current of a single nucleotide hindering signal, and molecular motors tend to fall off when controlling the movement of polynucleotides, resulting in sequencing accuracy reduce.
Covalent linkage is achieved by modifying CtPif1 helicase, especially introducing cysteine and linking molecules on the 1B and 2B domains, such as BMOE, Bis(PEG)2, etc., and enhancing the binding of polynucleotides to helicase. Stability, controlling the movement of polynucleotides through nanopores.
It improves the control ability of polynucleotides to pass through nanopores, ensures stable and gradual movement under the action of electric fields, and enhances the accuracy of nucleotide recognition, especially when sequencing long nucleotide sequences.
Smart Images

Figure CN117384878B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a modified CtPif1 helicase, in particular to a helicase capable of controlling the movement of a target polynucleotide through a biological nanopore and being particularly helpful for sequencing the polynucleotide, and belongs to the field of gene engineering and genetic engineering. Background Art
[0002] Nanopore sequencing technology developed in recent years is a new type of single-molecule sequencing technology. It uses electric field forces to drive single-stranded polynucleotides through nanoscale biological pore proteins embedded in insulating phospholipid membranes. Due to the different base sizes, each nucleotide molecule will produce a characteristic obstruction current when passing through the biological nanopore. The recorded characteristic current signals correspond to the sequence of the target nucleic acid.
[0003] In the "strand sequencing" method, a single polynucleotide chain passes through the biological nanopore to achieve the identification of the nucleotide sequence. Compared with other sequencing technologies, this sequencing technology has the advantages of low cost, no need for PCR amplification, fast and real-time convenience, long sequencing read length (more than 150kb), and the ability to directly sequence RNA and epigenetic modifications. It is considered a revolutionary technology in the field of sequencing and has immeasurable application value.
[0004] However, nanopore sequencing technology also has serious limitations. Under the action of the electric field, the speed at which a single-stranded polynucleotide passes through the nanopore is so fast that it is difficult to distinguish the current obstruction signal of a single nucleotide from the system noise. Therefore, in order to achieve the identification of nucleotides, chain sequencing uses a molecular motor bound to a polynucleotide to control the movement of the polynucleotide through the biological nanopore. However, the binding of the molecular motor and the polynucleotide is not static. When it controls the movement of the polynucleotide, especially when facing a very long nucleotide sequence, the molecular motor will fall off the polynucleotide. In addition, in the sequencing technology at the single-molecule level of chain sequencing, there are many unexpected single-molecule dynamic behaviors of the molecular motor. For example, some motor proteins will stagnate due to poor activity, thereby causing the pore to be blocked and reducing the sequencing throughput. Secondly, the displacement of the motor protein on the polynucleotide will slide forward, regress, and have uneven step lengths. These irregular single-molecule behaviors make it impossible for the motor protein to perfectly control the single-stranded polynucleotide to pass through the nanopore in a ratchet manner, thereby reducing the accuracy of base recognition. Therefore, there is an urgent need for a technology that can stably and efficiently control the passage of polynucleotides through biological nanopores. Summary of the invention
[0005] In response to the above technical problems, the present invention overcomes the problem in the prior art that the polynucleotides move through the nanopore too fast, and provides a DNA-dependent ATPase (CtPif1) helicase, which is very useful for controlling the perforation movement of polynucleotides during chain sequencing, and has better ability to control the movement of polynucleotides through the nanopore, and is particularly useful for polynucleotide sequencing.
[0006] The CtPif1 helicase core contains five domains: 1A (RecA-like motor) domain, 2A (RecA-like motor) domain, 1B (wedge domain), 2B (SH3-like) domain and 2C domain (extra structure unique to yeast). For the structural information of the corresponding CtPif1 protein, please refer to accession number: XP_002548760.1.
[0007] Among them, the 1A and 2A domains are mainly involved in the binding and hydrolysis of ATP. The 1B domain is composed of a short helix and an extended ring structure, which is called the "wedge region". The 2B domain adopts an SH-3-like folding method, and the track-like β-hairpin structure on it is close to the 1B domain. In addition, the 2C domain is an additional structure unique to yeast, which is important for maintaining the overall structural conformation of the protein.
[0008] Therefore, the present invention focuses on the two domains 1B and 2B when reducing the size of the opening by modifying the connection, and tends to reduce or close the opening by covalent connection.
[0009] There are two ways of connection. One is to connect through its own naturally occurring amino acids by replacing and inserting new amino acids, such as cysteine and unnatural amino acids. The other is to connect through linker molecules, which tend to connect between cysteines. Linker molecules include: BMOE, Bis(PEG)2 and Bis(PEG)3.
[0010] The present invention introduces cysteine into the two domains 1B and 2B respectively. The above-mentioned linker molecule usually contains two functional ends, which will be covalently linked to cysteine to achieve the connection between the two parts 1B and 2B, so that the bound polynucleotide will not dissociate from the helicase.
[0011] To this end, on the one hand, the present invention provides a modified CtPif1 helicase, which modifies four natural cysteines in the wild-type CtPif1 (313-781) amino acid sequence. All mutation sites of the present invention are described based on the wild-type CtPif1 (313-781) amino acid sequence, and the four natural cysteines are C61, C142, C168 and C222.
[0012] In a preferred embodiment of the present invention, the four natural cysteines are replaced with alanine (A), serine (S) or leucine (L).
[0013] On the other hand, the present invention provides a modified CtPif1 helicase, which introduces new cysteine for achieving connection, wherein the introduction sites on the 1B domain include R90, N91, K86, K87, S83, S80 and Q78; the introduction sites on the 2B domain include E389, T388, E387, V386, D385, T263, L264, P265, K267 and I268.
[0014] In a preferred embodiment of the present invention, the preferred mutation combination includes R90C, E387C, C61S, C142S, C168S and C222L.
[0015] In a further preferred embodiment of the present invention, the amino acid sequence of the helicase is as shown in SEQ ID NO.1.
[0016] In a preferred embodiment of the present invention, the helicase binds to an internal nucleotide of a single-stranded polynucleotide or a double-stranded polynucleotide.
[0017] On the other hand, the present invention provides a nucleotide sequence encoding the helicase of the present invention.
[0018] In a preferred embodiment of the present invention, the nucleotide sequence is shown as SEQ ID NO.2.
[0019] On the other hand, the present invention provides a complex formed by the helicase described in the present invention and bismaleimidoethane.
[0020] Another aspect of the present invention provides a construct comprising the helicase described in the present invention and a binding portion for binding to a polynucleotide.
[0021] In a preferred embodiment of the present invention, the binding moiety is selected from the group consisting of a eukaryotic single-stranded binding protein, a bacterial single-stranded binding protein, an archaic single-stranded binding protein, a viral single-stranded binding protein or a double-stranded binding protein.
[0022] On the other hand, the present invention provides the use of the helicase described in the present invention, or the nucleotide sequence encoding the helicase, or the complex containing the helicase, or the construct containing the helicase in characterizing the target polynucleotide or controlling the target polynucleotide to pass through the nanopore.
[0023] On the other hand, the present invention provides a kit for characterizing a target polynucleotide or controlling the passage of a target polynucleotide through a nanopore, the kit comprising the helicase described in the present invention or a nucleotide sequence encoding the helicase or a complex comprising the helicase or a construct comprising the helicase.
[0024] On the other hand, the present invention provides a device for characterizing a target polynucleotide or controlling the target polynucleotide to pass through a nanopore, wherein the device comprises the helicase described in the present invention or a nucleotide sequence encoding the helicase or a complex comprising the helicase or a construct comprising the helicase.
[0025] Another aspect of the present invention provides a method for characterizing a target polynucleotide or controlling a target polynucleotide to pass through a nanopore, comprising the following steps:
[0026] 1. contacting a target polynucleotide with a nanopore, and a helicase or a complex comprising the helicase or a construct comprising the helicase according to the present invention, so that the helicase, the complex or the construct controls the target polynucleotide to pass through the nanopore; and
[0027] 2. Obtain one or more characteristics of the interaction between the nucleotides in the target polynucleotide and the nanopore to characterize the target polynucleotide, wherein the construct comprises a helicase and a binding portion for binding the polynucleotide.
[0028] In a preferred embodiment of the present invention, the one or more characteristics are selected from the source, length, identity, sequence, secondary structure of the target polynucleotide or whether the target polynucleotide is modified.
[0029] In a preferred embodiment of the invention, said one or more characteristics are carried out by electrical and / or optical measurements.
[0030] In a preferred embodiment of the present invention, the target polynucleotide is single-stranded, double-stranded, or at least a portion is double-stranded.
[0031] In a preferred embodiment of the present invention, the nanopore is a transmembrane pore, and the transmembrane pore is a biological pore, a solid-state pore, or a biological and solid-state hybrid pore.
[0032] Another aspect of the present invention provides a vector comprising the nucleotide sequence of the helicase of the present invention.
[0033] In another aspect, the present invention provides a host cell comprising the nucleotide sequence of the helicase of the present invention or a vector comprising the nucleotide sequence.
[0034] Beneficial Effects
[0035] The present invention has demonstrated that the modified CtPif1 helicase can control the movement of polynucleotides through biological nanopores, especially under the action of electric field forces. The helicase can enable the target polynucleotide to move through the nanopore in a controllable and stepwise manner.
[0036] The specific CtPif1 helicase mutants provided by the present invention have improved ability to control the translocation of polynucleotides through nanopores, and these mutants usually have one or more modifications in the 1B or 2B domains. Therefore, the modified CtPif1 helicase provided by the present invention has at least one cysteine or non-natural amino acid inserted, and still maintains its ability to control the movement of polynucleotides.
[0037] The present invention also provides a modified CtPif1 helicase in which the 1B and 2B domains are covalently linked by a linker molecule, thereby improving the stability of the binding of the CtPif1 helicase of the present invention to the polynucleotide. In particular, when the length of the polynucleotide chain increases, the helicase of the present invention can still stably control the movement of the polynucleotide without falling off the polynucleotide. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 This is a diagram showing the result of SDS-PAGE gel electrophoresis purification of the CtPif1 helicase of the present invention;
[0039] M:Marker;
[0040] 1: Electrophoresis result diagram of the CtPif1 helicase of the present invention.
[0041] Figure 2 Schematic diagram of fluorescence analysis for detecting helicase activity.
[0042] Figure 3 It is a diagram of the SDS-PAGE gel electrophoresis results before and after the covalent cross-linking of the CtPif1 helicase of the present invention with bismaleimidoethane.
[0043] M:Marker;
[0044] 1: CtPif1 helicase sample of the present invention without covalent cross-linking of bismaleimidoethane;
[0045] 2: The CtPif1 helicase protein sample of the present invention covalently cross-linked with bismaleimidoethane.
[0046] Figure 4 It is a gel migration electrophoresis diagram of CtPif1 helicase binding to DNA before and after modification of the present invention.
[0047] 1: Pure annealed DNA substrate;
[0048] 2-4: Wild-type CtPif1 binds to DNA at room temperature after incubation with DNA substrate at molar ratios of 1:1, 5:1 and 10:1:
[0049] 5-7: The modified CtPif1 of the present invention binds to DNA after incubation with DNA substrate at room temperature at molar ratios of 1:1, 5:1 and 10:1.
[0050] Figure 5 is a schematic diagram of the DNA construct X used in the present invention.
[0051] A: 50 T;
[0052] B: Helicase used in the present invention;
[0053] C: 1 iSpC18 spacer;
[0054] D: SEQ ID NO: 3;
[0055] E: 2 iSpC18 spacers;
[0056] F: SEQ ID NO: 4;
[0057] G: SEQ ID NO: 5;
[0058] H: SEQ ID NO: 6 with a cholesterol tag at the 3' end.
[0059] Figure 6 is a schematic diagram of DNA construct Y used in the present invention.
[0060] A: 50 T;
[0061] B: Helicase used in the present invention;
[0062] C: 1 iSpC18 spacer;
[0063] D: SEQ ID NO: 3;
[0064] E: 2 iSpC18 spacers;
[0065] F: SEQ ID NO: 4;
[0066] K: SEQ ID NO: 7;
[0067] I: 30 T.
[0068] Figure 7 It is a schematic diagram of the current trajectory when the CtPif1 helicase of the present invention controls the displacement of the DNA construct X through the nanopore.
[0069] X-axis: time (s);
[0070] Y-axis: current (nA).
[0071] Figure 8 The present invention shows Figure 7 A magnified view of the region where the helicase controls the movement of the DNA construct X through the pore is shown.
[0072] X-axis: time (s);
[0073] Y-axis: current (nA). DETAILED DESCRIPTION
[0074] In order to better illustrate the purpose and advantages of the present method, the specific implementation content of the present invention is further described in detail in conjunction with the accompanying drawings and specific embodiments.
[0075] Example 1: Preparation of CtPif1 helicase protein
[0076] According to the amino acid sequence of the wild-type CtPif1 protein (accession number: XP_002548760.1, relevant website: https: / / www.ncbi.nlm.nih.gov / protein / XP_002548760.1 / ), its nucleic acid sequence was obtained by in vitro gene synthesis, and then the relevant codons were optimized using Escherichia coli as the host, and the codons were replaced with codons commonly used in Escherichia coli to obtain the optimized nucleic acid sequence of the CtPif1 protein. Then, it was connected and inserted into the pET28 expression vector through the two restriction enzyme sites of NdeⅠ and XhoⅠ. After the sequence was verified to be correct by sequencing, the recombinant expression plasmid of the CtPif1 helicase was finally obtained. Then, the nucleic acid sequence encoding the mutation combination R90C, E387C, C61S, C142S, C168S and C222L (SEQ ID NO.2) was obtained by site-directed mutagenesis using the overlapping PCR method.
[0077] The mutated recombinant plasmid was transformed into the BL21 (DE3) Escherichia coli expression host by heat shock method. In the process of induced expression, the host bacteria containing the expression plasmid were first cultured overnight at 37°C with LB medium containing kanamycin resistance, and then amplified at 37°C at a ratio of 1:100. When the OD (600) value reached 0.4-0.6, the culture was stopped and placed at 4°C for 1 hour for cooling treatment, and then 0.5mM isopropyl β-D-Thiogalactoside (IPTG) was added to induce expression at 16°C for 12-16h. Then, the bacteria were collected by centrifugation at 4°C and 15000rpm, and the bacteria were crushed by high pressure at 4°C by a high pressure crusher, and then the supernatant was collected by centrifugation at 4°C, and then the target protein was separated and purified step by step through a nickel column, a heparin column, a Q column and a molecular sieve, and finally a large amount of high-purity helicase mutant protein was obtained, and the sequence is shown in SEQ ID NO.1.
[0078] Attached Figure 1 The SDS-PAGE gel electrophoresis diagram of the purified CtPif1 helicase of the present invention is shown.
[0079] Example 2: Fluorescence assay to analyze the unwinding activity of CtPif1 (313-781) helicase
[0080] Attached Figure 2 Schematic diagram of fluorescence analysis for detecting helicase activity.
[0081] As attached Figure 2 As shown in (1), the fluorescent substrate chain (final concentration 100nM, d, SEQ ID NO: 8) has a single-stranded DNA portion of 20 bases at the 5' end and a double-stranded DNA portion of 18 bases hybridized, and its 3' end has a fluorescent group (Cy3, f). The upper short chain (c, SEQ ID NO: 9) that is complementary to it has a fluorescent quenching group (BHQ-1, e) at the 5' end. When the two chains are complementary, the fluorescence of Cy3 (f) will be quenched by BHQ-1 (e), and the substrate is basically non-fluorescent.
[0082] During the experiment, Figure 2 As shown in (2), the CtPif1 (313-781) helicase binds to the 5' single-stranded DNA portion of the fluorescent substrate, and after the addition of ATP (2 mM) and MgCl2 (2 mM), it shifts in the 5'-3' direction and unwinds the double-stranded portion.
[0083] Subsequently, as attached Figure 2As shown in (3), the excess capture strand (b, SEQ ID NO: 10) preferentially forms complementary pairs with the short strand (c) to prevent re-annealing between the initial substrates, and the released substrate backbone (d) emits fluorescence.
[0084] The results showed that in 300 mM NaCl buffer (25 mM Tris-HCl pH 7.5, 2 mM ATP, 2 mM MgCl2, 300 mM NaCl), CtPif1 (313-781) helicase unwinds the fluorescent substrate over time, and the substrate changes from being essentially non-fluorescent to emitting fluorescence, indicating that CtPif1 (313-781) helicase has unwinding activity.
[0085] Example 3: Preparation of CtPif1-R90C, E387C, C61S, C142S, C168S and C222L mutation combinations
[0086] Among them, CtPif1-R90C, E387C, C61S, C142S, C168S and C222L are SEQ ID NO: 1 having the mutation combination CtPif1-R90C, E387C, C61S, C142S, C168S and C222L connected to bismaleimidoethane.
[0087] In this case, a covalent link was formed between cysteines at positions 90 and 387 in the original sequence of CtPif1 by reaction with a bismaleimidoethane linker molecule.
[0088] Add 1 μL 1M DTT to 100 μl CtPif1-R90C, E387C, C61S, C142S, C168S and C222L (SEQ ID NO: 1 with the mutation combination R90C, E387C, C61S, C142S, C168S and C222L, stored in 25 mM Tris-HCl pH 7.5, 500 mM NaCl, 10% glycerol, 2 mM EDTA) and incubate at room temperature for 30 minutes.
[0089] The buffer was replaced with PBS buffer (pH 7.5) by a 0.5 ml Zeba desalting column (7k MWCO) to obtain 100 μl of sample. 1 μl of 10 mM bismaleimidoethane was added and incubated at 20 rpm for 1 hour at room temperature, after which 1 μl of 1 M DTT was added to terminate the reaction. The cross-linking results were analyzed using a 4-10% polyacrylamide gel.
[0090] Attached Figure 3The figure shows the changes of the CtPif1-R90C, E387C, C61S, C142S, C168S and C222L mutant combinations of the present invention before and after covalent crosslinking with bismaleimidoethane. Compared with sample 1 without crosslinking, sample 2 after covalent crosslinking has a certain degree of displacement, indicating that sample 2 has intramolecular crosslinking with bismaleimidoethane. The reaction of the CtPif1 mutants of the present invention with the linker molecules has almost reached a yield of 100%.
[0091] Example 4: Gel shift assay to measure the ability of modified CtPif1 helicase to bind DNA
[0092] The DNA substrates required for gel shift assay were prepared by annealing (SEQ ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13 were annealed at a molar concentration ratio of 1: 1.1: 1.1, with a final concentration of 10 uM), and then mixed with wild-type CtPif1 (accession number: XP_002548760.1), CtPif1-R90C, E387C, C61S, C142S, C168S and C222L (SEQ ID NO: 1 with the mutation combination R90C, E387C, C61S, C142S, C168S and C222L) at a molar ratio of 1: 1, 1: 5 and 1: 10, respectively, in a buffer (25 mM Tris-HCl pH 7.2, 100 mM NaCl, 10% glycerol, 1 mM The mixture was incubated in EDTA at room temperature for one hour to obtain a final concentration of 2.5 uM CtPif1 helicase and 500 nM DNA in the final reaction solution. The total reaction volume was 20 μL.
[0093] Add bismaleimidoethane to the corresponding helicase mutant samples to a final concentration of 10 μM and incubate at room temperature for 1 hour. Then, use 4%-10% TBE gel for detection, run at 120V for 1.5 hours, and then observe the DNA bands under UV light by Gel Red staining.
[0094] Attached Figure 4The ability of CtPif1 helicase to bind DNA before and after modification of the present invention is shown, and the results show the effect of CtPif1 helicase on DNA binding ability before and after modification. Sample 1 represents a simple DNA substrate that is not bound to CtPif1 helicase; when wild-type CtPif1 helicase and DNA substrate are mixed according to different molar ratios such as 1:1, 5:1 and 10:1, bands of binding DNA substrate and wild-type CtPif1 helicase appear on the electrophoresis graph, that is, samples 2-4 have new bands that are biased upward relative to sample 1; and when CtPif1 helicase is modified, compared with samples 2-4, the simple DNA substrate bands that are biased downward in samples 5-7 are reduced, while the binding bands that are biased upward are increased, which indicates that the binding ability of the modified CtPif1 to polynucleotides is significantly enhanced.
[0095] Example 5: CtPif1-R90C, E387C, C61S, C142S, C168S and C222L-bismaleimidoethane has the ability to control the movement of the complete DNA construct X through the nanopore
[0096] Among them, CtPif1-R90C, E387C, C61S, C142S, C168S and C222L-bismaleimidoethane is SEQ ID NO: 1 having the mutation combination R90C, E387C, C61S, C142S, C168S and C222L connected to bismaleimidoethane.
[0097] Preparation as attached Figure 5 DNA construct X is shown.
[0098] First, primers were designed, which contained sequences A, C, D, E and F, and then used to amplify a 1000 base sequence (G) on λDNA. The obtained PCR product was purified and then annealed and hybridized with sequence H at a molar ratio of 1:1.1, thereby obtaining the final DNA construct X.
[0099] The prepared DNA construct X (final concentration 0.1 nM) was preincubated with CtPif1-R90C, E387C, C61S, C142S, C168S and C222L-bismaleimidoethane (final concentration 10 nM) in a buffer (10 mM Hepes, pH 8.0, 100 Mm KCl, 10% glycerol) at room temperature for 30 minutes.
[0100] Electrical signal measurements were obtained from Csgg nanopores embedded in DPhPC phospholipid bilayers in buffer (600 mM KCl, 75 mM K3[Fe(CN)6, 25 mM K4[Fe(CN)6]·3H2O, 100 mM Hepes, pH 8.0). After achieving single pore insertion into the phospholipid bilayer, 2 ml of buffer (600 mM KCl, 75 mM K3[Fe(CN)6, 25 mM K4[Fe(CN)6]·3H2O, 100 mM Hepes, pH 8.0) was flowed through the system to remove excess residual nanopores. The pre-incubated sample, ATP (final concentration 2 mM) and MgCl2 (final concentration 10 mM) were then flowed together into the single nanopore experimental system (total volume 100 μL) and the signal was measured at a constant voltage of +180 mV for 6 h (including a potential 2 s voltage reversal of -180 mV).
[0101] As attached Figure 7 As shown, it was observed that the CtPif1-R90C, E387C, C61S, C142S, C168S and C222L (SEQ ID NO: 1 with the mutation combination R90C, E387C, C61S, C142S, C168S and C222L) helicase was able to control the movement of DNA construct X through the nanopore. The helicase-controlled DNA movement duration of 2.5 seconds corresponds to the movement of a DNA construct of nearly 1000 bp through the Csgg nanopore.
[0102] Among them, Figure 8 A magnified view of a portion of the region where the helicase of CtPif1-R90C, E387C, C61S, C142S, C168S and C222L (SEQ ID NO: 1 with the mutation combination R90C, E387C, C61S, C142S, C168S and C222L) controls DNA movement is shown. The results show that the mutants are able to control the movement of the complete DNA construct X through the nanopore.
[0103] Example 6: Ability of wild-type CtPif1 and CtPif1-R90C, E387C, C61S, C142S, C168S and C222L-bismaleimidoethane to control movement of intact DNA construct Y through a nanopore
[0104] Among them, CtPif1-R90C, E387C, C61S, C142S, C168S and C222L-bismaleimidoethane is SEQ ID NO: 1 having the mutation combination R90C, E387C, C61S, C142S, C168S and C222L connected to bismaleimidoethane.
[0105] Preparation as attached Figure 6 DNA construct Y is shown.
[0106] First, an upstream primer containing A, C, D, E and F sequences and a downstream primer containing 30 A's at the 5' end were designed, and then they were used to amplify a 4115-base sequence (K) on λDNA, so that a poly-T sequence (I) was added to the 3' end of the K sequence. The obtained PCR product was purified and annealed and hybridized with sequence H at a molar ratio of 1:1.1 to obtain the final DNA construct Y.
[0107] The prepared DNA construct Y (final concentration 0.1 nM) was preincubated with wild-type CtPif1 (accession number: XP_002548760.1) and CtPif1-R90C, E387C, C61S, C142S, C168S and C222L-bismaleimidoethane (final concentration 10 nM) in buffer (10 mM Hepes, pH 8.0, 100 mM KCl, 10% glycerol) at room temperature for 30 minutes.
[0108] Electrical signal measurements were obtained from Csgg nanopores embedded in DPhPC phospholipid bilayers in buffer (600 mM KCl, 75 mM K3[Fe(CN)6, 25 mM K4[Fe(CN)6]·3H2O, 100 mM Hepes, pH 8.0). After achieving single pore insertion into the phospholipid bilayer, 2 ml of buffer (600 mM KCl, 75 mM K3[Fe(CN)6, 25 mM K4[Fe(CN)6]·3H2O, 100 mM Hepes, pH 8.0) was flowed through the system to remove excess residual nanopores. The pre-incubated sample, ATP (final concentration 2 mM) and MgCl2 (final concentration 10 mM) were then flowed together into the single nanopore experimental system (total volume 100 μL) and the signal was measured at a constant voltage of +180 mV for 6 h (including a potential 2 s voltage reversal of -180 mV).
[0109] The results showed that adding the complex formed by CtPif1 helicase and DNA construct into the Csgg nanopore system can generate typical nucleic acid permeation current signals. Wild-type CtPif1 helicase monomers and CtPif1-R90C, E387C, C61S, C142S, C168S and C222L-bismaleimidoethane can all control the permeation movement of DNA construct Y.
[0110] Statistical comparison of the same number of DNA pore trajectories controlled by the helicase revealed that for the wild-type CtPif1 helicase monomer, typical multi-T (I region) pore current signals were observed in only a small proportion of the electrical signal trajectories.
[0111] However, for CtPif1-R90C, E387C, C61S, C142S, C168S, and C222L-bismaleimidoethane, typical pore-passing signals of poly-T (I region) were observed in most of the electrical signal traces, which means that the helicase reached the 3' end of DNA construct Y.
[0112] The above results indicate that CtPif1-R90C, E387C, C61S, C142S, C168S and C222L-bismaleimidoethane have better ability to control DNA perforation movement than wild-type CtPif1.
[0113] All sequences used in the present invention are shown in Table 1.
[0114] Table 1 Sequences used in the present invention
[0115]
[0116]
[0117]
[0118]
[0119] The above embodiments are only preferred embodiments of the present invention, and the present invention should not be limited to the contents disclosed in the embodiments and drawings. Any equivalent or modification completed without departing from the spirit disclosed in the present invention shall fall within the scope of protection of the present invention.
Claims
1. A modified CtPif1 helicase, characterized in that The amino acid sequence of the helicase is shown in SEQ ID NO.
1.
2. A nucleic acid encoding the helicase according to claim 1.
3. The nucleic acid according to claim 2, characterized in that The nucleotide sequence of the nucleic acid is shown in SEQ ID NO.
2.
4. A complex formed by the helicase described in claim 1 and bismaleimidoethane.
5. A construct, characterized in that The construct comprises the helicase of claim 1 or the complex of claim 4 and a binding portion for binding to a polynucleotide.
6. The construct according to claim 5, characterized in that The binding moiety is selected from a eukaryotic single-stranded binding protein, a bacterial single-stranded binding protein, an archaic single-stranded binding protein, a viral single-stranded binding protein or a double-stranded binding protein.
7. Use of the helicase according to claim 1, the nucleic acid according to claim 2 or 3, the complex according to claim 4, or the construct according to claim 5 or 6 in controlling the passage of a target polynucleotide through a nanopore.
8. A kit for controlling the passage of a target polynucleotide through a nanopore, characterized in that: The kit comprises the helicase of claim 1 or the nucleic acid of claim 2 or 3 or the complex of claim 4 or the construct of claim 5 or 6.
9. A device for controlling a target polynucleotide to pass through a nanopore, characterized in that: The device comprises the helicase of claim 1 or the nucleic acid of claim 2 or 3 or the complex of claim 4 or the construct of claim 5 or 6.
10. A method for controlling a target polynucleotide to pass through a nanopore, characterized in that: The following steps are involved: (1) contacting a target polynucleotide with a nanopore, and the helicase of claim 1 or the complex of claim 4 or the construct of claim 5 or 6, such that the helicase, complex or construct controls the target polynucleotide to pass through the nanopore; and (2) obtaining one or more characteristics of the interaction between nucleotides in the target polynucleotide and the nanopore to characterize the target polynucleotide, wherein the construct comprises a helicase and a binding portion for binding the polynucleotide.
11. The method according to claim 10, characterized in that The one or more characteristics are selected from the source, length, identity, sequence, secondary structure of the target polynucleotide or whether the target polynucleotide is modified.
12. The method according to claim 10 or 11, characterized in that: The one or more characteristics are performed by electrical and / or optical measurements.
13. The method according to claim 10 or 11, characterized in that: The target polynucleotide is single-stranded, double-stranded, or at least partially double-stranded.
14. The method according to claim 12, characterized in that The target polynucleotide is single-stranded, double-stranded, or at least partially double-stranded.
15. The method according to claim 10 or 11, characterized in that: The nanopore is a transmembrane pore, and the transmembrane pore is a biological pore, a solid-state pore, or a biological and solid-state hybrid pore.
16. The method according to claim 12, characterized in that The nanopore is a transmembrane pore, and the transmembrane pore is a biological pore, a solid-state pore, or a biological and solid-state hybrid pore.
17. The method according to claim 13, characterized in that The nanopore is a transmembrane pore, and the transmembrane pore is a biological pore, a solid-state pore, or a biological and solid-state hybrid pore.
18. The method according to claim 14, characterized in that The nanopore is a transmembrane pore, and the transmembrane pore is a biological pore, a solid-state pore, or a biological and solid-state hybrid pore.
19. A vector comprising the nucleic acid of claim 2 or 3.
20. A host cell comprising the nucleic acid of claim 2 or 3 or comprising the vector of claim 19.
